References
- Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review. Bethesda, MD: National Cancer Institute; 1975–2015. https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER website, April 2018.
- Bhatt VR, Gundabolu K, Koll T, et al. Initial therapy for acute myeloid leukemia in older patients: principles of care. Leuk Lymph. 2018;59:29–41.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Acute myeloid leukemia. Version 3; 2017 – [cited 2017 June 6]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
- Kantarjian HM, Wolff RA. The MD Anderson manual of medical oncology. New York, NY: McGraw Hill Education; 2016
- Kantarjian H, O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098.
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
- Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417–4423.
- Burnett AK, Milligan D, Prentice AG, et al. A Comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124.
- Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs. conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–299.
- Porter M. What is value in health care? N Engl J Med. 2010;363:2477–2481.
- Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. JCO. 2016;34:2925–2934.
- Carlson RW, Jonasch E. NCCN evidence blocks. J Natl Compr Canc Netw. 2016;14:616–619.
- Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–2677.
- Al-Ali HK, Jaekel N, Niederwieser D. The role of hypomethylating agents in the treatment of elderly patients with AML. J Geriatr Oncol. 2014;5:89–105.
- Sarmiento Maldonado M, Ocqueteau Tachini M, Pilcatne J, et al. Response and survival in acute myeloid leukemia patients not candidates to transplantation treated with azacitidine versus palliative treatment: a retrospective study. Medwave. 2015;15:e6207.
- Alibhai SMH, Leach M, Kermalli H, et al. The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol. 2007;64:19–30.
- Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98:208–216.
- Oliva NE, Nobile F, Alimena G, et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011;96:696–702.
- Gavillet M, Noetzli J, Blum S, et al. Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine. Haematologica. 2012;97:1929–1931.
- Cannas G, Fattoum J, Boukhit M, et al. Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly. Transfus Clin Biol. 2015;22:341–347.